β-羟基-β-甲基丁酸口服补充对髋部骨折老年患者的影响

doi:10.16689/j.cnki.cn11－9349/r.2019.04.014

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (824 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the clinical efficacy of β-hydroxy-β-methylbutyrate acid in the treatment of muscular dystrophy in elderly patients with hip fracture. Methods From January 2018 to March 2019, the elderly patients with hip fracture who met the inclusion criteria were randomly divided into experimental group （n=30） and control group （n=28）. The control group was given conventional nutrition treatment, and the experimental group was treated with HMB on the basis of the control group. The weight, total protein, albumin, creatinine, grip strength, appendant skeletal muscle mass （ASMM）, the number of cases of pulmonary infection and the number of cases with Barthel index>40 were monitored and compared between the two groups at three time points （0, 3, 6 weeks）. ResultsThe body weight, total protein, albumin and creatinine of the patients in the experimental group increased significantly （P<0.05）. The ASMM of experimental group and control group decreased, but the difference was statistically significant （P<0.05）. There was no significant difference in grip strength （P>0.05）. The incidence of pulmonary infection in the control group was significantly higher than that in the experimental group （P<0.05）. The number of people whose Barthel index was more than 40 points was significantly higher than that of the control group （P<0.05）. ConclusionThrough the clinical study of HMB in the treatment of myopenia in elderly patients with hip fracture, it has obvious effects in inhibiting muscle and protein decomposition, increasing lean muscle and improving malnutrition status of patients. The incidence of pulmonary infection is relatively small, which can reduce the risk of death of patients, promote their rehabilitation and enhance their self-care ability to a certain extent. Prevention and reduction of muscle loss in hospitalized patients is one of the treatment factors clinicians should consider, so HMB should be better applied in the field of nutrition therapy. Whether HMB is effective for other diseases, such as tumors, liver transplantation and so on, still needs a lot of clinical experiments and evaluation methods to further study its clinical effect.

Key words： β-hydroxy-β-methylbutyrate Hip fracture Elderly patients Sarcopenia Nutritional therapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	1ZUO Dan
	2HUANG Biao
	3LUO Chun-li
	4ZHONG Lan

Cite this article:

1ZUO Dan,2HUANG Biao,3LUO Chun-li, et al. Effect of oral supplement of β-hydroxy-β-methylbutyric acid on elderly patients with hip fracture[J]. Electron J Metab Nutr Cancer, 2019, 6(4): 462-467.

URL:

http://182.92.200.144/EN/10.16689/j.cnki.cn11－9349/r.2019.04.014 OR http://182.92.200.144/EN/Y2019/V6/I4/462

1.Kristiansson J, Olsen F, Hagberg E, et al. Prolonged vasopressor support during hip-fracture surgery is a risk factor for enhanced mortality. Acta anaesthesiologica Scandinavica. 2019；63（1）:46-54.
2.Ensrud KE. Epidemiology of fracture risk with advancing age. J Gerontol A Biol Sci Med Sci. 2013；68（10）:1236-1242.
3.Vellas B, Fielding R, Miller R, et al. Designing drug trials for sarcopenia in older adults with hip fracture －a task force from the International Conference on Frailty and Sarcopenia Research （ICFSR）. J Frailty Aging. 2014；3（4）:199-204.
4.Hida T, Ishiguro N, Shimokata H, et al. High prevalence of sarcopenia and reduced leg muscle mass in Japanese patients immediately after a hip fracture.Geriatr Gerontol Int. 2013；13（2）:413-420.
5.Rosenberg IH. Summary comments:epidemiological and methodological problems in determining nutritional status of older persons. Am J Clin Nutr.1989；50:1231-1233.
6.Rosenberg IH. Sarcopenia:origins and clinical relevance. J Nutr.1997；127（5 Suppl）:990S-991S.
7.Morley JE, Baumgartner RN, Roubenoff R, et al. Sarcopenia. J Lab Clin Med. 2001；137（4）:231-243.
8.Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: european consensus on definition and diagnosis. Age Ageing. 2010；39（4）:412-423.
9.Larsson L, Degens H, Li M.Sarcopenia:aging related loss of muscle mass and function. Physiological Reviews. 2019；99（1）:427-511.
10.Vincenzo M, Francisco U, Concetta M, et al. Effectiveness of nutri tional supplementation on sarcopenia and recovery in hip fracture patients.A multi-centre randomized trial. Maturitas. 2017；101:42-50.
11.洪维, 朱晓颖, 程群, 等. 老年髋部骨折患者肌肉减少症与骨密度的关系. 中华骨质疏松和骨矿盐疾病杂志. 2014；7（2）:106-112.
12.Kovarik M, Muthny T, Sispera L, et al. Effects of beta-hydroxy-beta-methylbutyrate treatment in different types of skeletal muscle of intact and septic rats. J Physiol Biochem. 2010；66 （4）:311-319．
13.王树英, 阎渭清. HMB对ICU肌肉减少患者的作用探讨. 肿瘤代谢与营养电子杂志. 2018；5（2）:212-215.
14.Bulgakova SV, Treneva EV, Zakharova NO, et al. The sarcopenia:a multicomponent strategy for therapy （review of literature）.Adv Gerontol. 2019；32（3）:405-414.
15.Jeschke MG, Chinkes DL, Finnerty CC, et al. Pathophysiologic response to severe burn injury. Ann Surg. 2008；248（3）:387-401.
16.Tisdale MJ. Mechanisms of cancer cachexia.Physiol Rev. 2009；89（2）:381-410.
17.Engelson ES, Agin D, Kenya S, et al. Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women. Metabolism. 2006；55（10）:1327-1336.
18.Brown AD, Close GL, Sharples AP, et al. Murine myoblast migration:influence of replicative ageing and nutrition. Biogerontology. 2017；18（6）:947-964.
19.Nissen SL, Abumrad NN. Nutritional role of the leucine metaboliteβ-hydroxy-β-Methylbutyrate （HMB）. J Nutr Biochem.1997；8:300-311.
20.Nissen S, Sharp R, Ray M, et al. The effect of the leucine metabolite-β-hydroxy-β-methylbutyrate on muscle metabolism during resistance exercise training. J Appl Physiol. 1996；81（5）:2095-2104.
21.Hao Y, Jackson JR, Wang Y, et al. β-Hydroxy-β-methylbutyrate reduces myonuclear apoptosis during recovery from hind limb suspension induced muscle fiber atrophy in aged rats. Am J Physiol Regul Integr Comp hysiol. 2011；301（3）:701-715.
22.苏琳, 刘爽, 董碧蓉. 营养与肌肉减少症. 肿瘤代谢与营养电子杂志. 2019；6（1）:26-34.
23.文星, 曾翔, 唐华. β-羟基-β-甲基丁酸治疗肿瘤恶病质的研究进展. 医学综述. 2019；25（3）:459-463,469.
24.鲁攀攀, 马彬彬,李荥娟, 等. 老年髋部骨折患者术前营养不良的危险因素分析. 中华老年骨科与康复电子杂志. 2018；4（3）:145-150.
25.张付峰, 卢晓琴. 肌肉减少症与肿瘤化疗. 肿瘤代谢与营养电子杂志. 2019；6（1）:110-115.
26.谢华, 陈敏, 乔莉华, 等. 握力指数在社区老年人营养不良筛查中的应用价值. 江苏大学学报（医学版）. 2018；28（6）:503-506,511.
27.Vogt BP, Borges MCC, Goés CR, et al. Handgrip strength is an independent predictor of all cause mortalit in maintenance dialysis patients. Clin Nutr. 2016；5（6）:1429-1433．
28.中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2017年版）. 中华糖尿病杂志. 2018；10（1）:4-67.
29.Zhang J, Upala S, Sanguankeo A. Ｒelationship between vitamin D deficiency and diabetic retinopathy: a meta-analysis. Can J Ophthalmol. 2017；52（Suppl 1）:S39-S44.
30.许倩. 老年髋部骨折病人不同危险因素对围术期发生肺部感染的影响临床研究.世界最新医学信息文摘. 2019；19（45）:73-74,77.
31.李莉, 陈念, 柯柳, 等. 老年髋部骨折围术期肺部感染危险因素分析. 中国组织工程研究. 2014；18（35）:5736-5740.
32.Mahoney FI, Barthel DW. Functional evalutation:The Barthel Index. Md State Med J. 1965；14:61-65.
33.Buurman BM, van Munster BC, Korevaar JC, et al. Variability in measuring （instrumental） activeties of daily living functioning and functional decline in hospitalized older medical patients: a systematic review. J Clin Epidemiol. 2011；64（6）:619-627.
34.González N, Ilbao A, Orjaz MJ, et al. sychometric characteristics of the Spanish version of the Barthel index. Aging Clin Exp Res. 2018；30（5）:489-449.